שולי רווח תפעולי ממכירות: Lyell (LYEL)

Lyell Immunopharma develops T-cell therapies to combat solid tumors by preventing immune cell exhaustion. Operating profitability demonstrates the financial impact of these developments, where 0.00 captures the current value of the indicator. Negative values are driven by a general liquidity deficit due to R&D expenditures, although unique patents on cell rejuvenation create a significant technological barrier for competitors.
Lyell Immunopharma - פילוחים אנליטיים ומדדי מפתח (LYEL)

Operating margin reflects the efficiency of profit generation from core business processes before accounting for financial expenses and taxes. The metric is calculated as the ratio of operating income to revenue, demonstrating the model's sensitivity to costs. Analyzing the actual operating margin allows for an assessment of the internal profitability of assets. For Lyell Immunopharma (LYEL), negative values are expected due to extensive R&D expenditures. A high liquidity reserve and the management's scientific expertise ensure the company's stability despite the absence of current operating profit.